PTO/SB/05 (06-03)
Approved for use through 07/31/2003. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE nd to a collection of information unless it displays a valid OMB control number

U.S. P.	UTILITY			ney Docket No.	PC11865A					
	PATENT APPLICATIO	First I	Inventor	George J. Quallich						
= 7	TRANSMITTAL		Title		PHARMACEUTICALLY ACCEPTABLE SALT OF SERTRALINE AND PHARMACEUTICAL COMPOSITIONS THEREOF					
(Only for new no	napplications under 37C.F.R. §1.53(b))		Expre	ess Mail Label No.	EL 874867925 US					
	APPLICATION ELEMENTS apter 600 concerning utility patent application	contents.	Mail Stop <u>Patent Application</u> Commissioner for Patents Box 1450 Alexandria, VA 22313-1450							
2. (So	Fee Transmittal Form (e.g., PTO/SB/17 ubmit an original, and a duplicate for fee processi Applicant claims small entity status See 37 CFR 1.27 Specification [Total Pages]		 CD-ROM or CD-R in duplicate, large table or computer Program (Appendix) Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Copy (CRF) 							
<u></u> -	 preferred arrangement set forth below) Descriptive title of the Invention Cross References to Related Applica Statement Regarding Fed sponsored Reference to sequence listing, a table or a computer program listing appendence Background of the Invention 	i R&D e,	b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies) ii. Paper c. Statement verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of Attorney (when there is an assignee) 11. English Translation Document (if applicable)							
	 Brief Summary of the Invention Brief Description of the Drawings (if the Detailed Description Claim(s) Abstract of the Disclosure 	filed)								
- 🖂	Drawing(s) (35 U.S.C. 113) [Total sheets	,	12.	Information Di Statement (ID		Copies of IDS Citations				
3. <u>(</u>	Dath or Declaration Total pages a. Newly executed (original or cop b. Copy from a prior application (37 CF (for continuation/divisional with Box: i. DELETION OF INVE Signed statement attached deleting	y) R §1.63(d)) 18 completed) NTOR(S)	13. 14. 15.	14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed)						
	named in the prior application, see 1.63(d)(2) and 1.33(b).	37 CFR	(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.							
6	Application Data Sheet. See 37 CFR 1.	76	17.	Other:						
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76. Continuation Divisional Continuation-in-part (CIP) of prior application No:										
			£	p.						
Prior application information: Examiner Group/Art Unit:										
19. CORRESPONDENCE ADDRESS										
Customer Number 23913 or Correspondence address below										
Name										
Address										
City		State			Zip Code					
Country	/) \ To	elephone			Fax					
NAM	E (Print/type) A. David Joran		Regist	tration No. (Attorney	/Agent)	37,858				

This collection of information is required by 87 CFB 53(a). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USE. 122 and 37 CFR 1/14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL						Complete if Known							
for FY 2004						Application Number Not yet known							
										oncurrently Herewith			
Effective 10/01/2003. Patent fees are subject to annual revision.										eorge J. Quallich			
·					Examiner Name								
Applicant claims small status. See 37 CFR 1.27 Total Amount of Payment (\$)770.00						Art Unit Attorney Docket No. PC				11865A	 		
METHOD OF PAYMENT (check all that apply)					FEE CALCULATION (continued)								
Check Credit Card Money Other None				3. ADDITIONAL FEES									
Order					Large Entity Small Entity								
☑ Deposit Account:						Fee (\$)	Fee Code	Fee (\$)		Fee Description			
Deposit Account Number	unt				1051	130	2051	65	Surcharge	,			
Deposit Account	Pfizer Inc				1052	50	2052	25	Surcharge				
The Director is authorized to: (check all that apply)						130	1053	130	Non-Engli				
☐ Charge fee(s)	indicated be	elow	☐ Credit any ov	erpayments	1812	2,520	1812	2,520	For fling a request for Ex Parte reexamination				
☐ Charge any additional fee(s) or any underpayment of fee(s)					1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action				
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.					1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action				
FEE CALCULATION						110	2251	55	Extension for reply within first month				
1. BASIC FILING FEE						420	2252	210	Extension	Extension for reply within second month			
Large Entity	Large Entity Small Entity					950	2253	475	· •	Extension for reply within third month			
Fee Fee Code (\$)	Fee Code	Fee (\$)			1254	1,480	2254	740	Extension	for reply within fou	irth month		
1001 770	2001	385	Fee Description Utility filing fee	Fee Paid	1255	2,010	2255	1,005	; Extension	for reply within fifth	n month		
1002 340	2002	170	Design filing fee	⊢ ′′′₀	1401	330	2401	165	Notice of				
1003 530	2203	265	Plant filing fee		1402	330	2402	165		ief in support of an	appeal		
1004 770	2004	385	Reissue filing fee		1403	290	2403	145	Request f	or oral hearing			
1005 160	2005	80	filing fee		1451	1,510	1451	1,510	Petition to	institute a public use p	roceeding		
					1452	110	2452	55	Petition to	revive unavoidable	е		
Subtotal (1)s \$ 770				1453	1,330	2453	665	Petition to	etition to revive – unintentional				
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE				1501	1,330	2501	665	Utility issu	Utility issue fee (or reissue)				
Extra Claims Fee from Fee Paid					1502	1502 480 2502 240 Design issue fee							
below Total Claims 27 - 20** = 7 x 18 = 0.00				1503	640	2503	320	Plant issu	nt issue fee				
Independent	1	- 3 =	0 x 86	= 0.00	1460	130	1460	130	Petitions t	o the Commissione	er		
Claims	لـــا			0.00	1807	50	1807	50	D	a faa wadaa 27 OF	D 4 47(a)		
Multiple Depende	iii.		[0	= 0.00	1806	50 180	1806	50 180		g fee under 37 CFF on of Information Disolo			
Large Entity Small Entity				1800	100	1800	100	Submissio	on or incomagon beau	BUIESHIN			
Fee Fee	Fee	Fee	Fee Description		8021	40	8021	40		each patent assig		—	
Code (\$) 1202 18	2202	(\$) 9	Claims in excess of 20		1809	770	2809	385	Filing a su	pperty (times number of properties) ng a submission after final rejection			
1201 86	2201	43	Independent claims in	excess of 3	1810	770	2810	385		additional invention			
1203 290	2203	145	Multiple dependent cla	im, if not paid	1801	770	2801	385		examined (37 CFR 1.129(b)) Request for Continued Examination (RCE)			
1204 86	2204	43	**Reissue independen	t claims over original patent	1802	900	1802	900	Request for expedited examination of a design application				
1205 18 2205 9 **Reissue independent claims over original patent						Other Fee (specify)							
(\$) 0.00													
		id, if gre	eater; For Reissues, se	e above	*Reduce	ed by Basic	Filing F			f applicable)	(\$)		
SUBMITTED BY Name (Printed/Type) A. David Joran						tration No	. 37,8		ompiete f	f applicable) Telephone	212-733-	3381	
Name (Printed Type) A. David Joran						ney Agent							
Signature		L		/									

Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and /or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-pto-9199 and select option2.